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Introduction
Treatments for chronic obstructive pulmonary disease 
(COPD) can be aimed at different aspects of the 
disease, such as improving airflow, providing symptom 
relief, modifying or preventing exacerbations or, most 
ambitiously, modifying or altering the disease process. 
Until recently, medications for the treatment of COPD 
have been approved by the United States Food and 
Drug Administration (FDA) primarily on the basis of 
improvements in lung function, as measured by forced 
expiratory volume in 1 sec (FEV1). However, there is only 
a weak association between FEV1 and exercise capacity, 
breathlessness, health status and exacerbations.1 
Additionally, improvements in other aspects of the 
disease, such as a reduction in inflammation or extra-
pulmonary consequences of the disease, may have little 
relationship to improvement in airway calibre. 
In May 2016 the FDA issued revised guidance for 
the development of new treatments for COPD. For 
the first time the guidance included information on 
the use of the St George’s Respiratory Questionnaire 
(SGRQ) to demonstrate improvements in health-
related quality of life (HRQL) in COPD clinical trials 
for the development of new drugs. This guidance allows 
companies developing treatments to use the SGRQ 
with confidence. It can be used either as a co-primary 
endpoint, along with another measure of efficacy, or 
as a secondary endpoint to support changes in other 
endpoints to make a clinically convincing argument of 
efficacy.
This new guidance is the final outcome of work begun 
in 2010 when the FDA, in collaboration with the COPD 
Foundation, the National Heart Lung and Blood Institute 
(NHLBI) and scientists from the pharmaceutical 
industry and academia, conducted a workshop to 
survey available information that could contribute to 
the qualification of outcome measures that could be 
used in the development of new treatments for COPD. 
As a result of this workshop, the COPD Biomarkers 
Qualification Consortium (CBQC) was established to 
improve the speed and efficiency of clinical research by 
driving the approval of new drug development tools and 
demonstrating the validity and reliability of existing 
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research tools. One of the first projects of the CBQC 
was qualification of  the SGRQ as a measure of HRQL 
designed to assess health status in patients with chronic 
airflow limitation.2,3 
Although the SGRQ was previously mentioned in 
FDA guidance and already accepted by European 
regulators, at the 2010 workshop the FDA indicated a 
need for analyses that demonstrated the performance 
properties of the SGRQ total score, specifically in terms 
of cross-sectional validity, longitudinal patterns and 
trajectories of change, and predictive validity, with the 
latter as an indicator of disease progression, morbidity, 
and mortality.
CBQC members developed an integrated database 
combining data from both industry- and government-
sponsored (i.e., NHLBI) studies. An analysis plan was 
implemented to examine the cross-sectional validity of 
the SGRQ when compared to other outcomes, including 
clinical disease characteristics and demographics, and 
to understand the longitudinal patterns and trajectories 
of change in health status by evaluating intra- and inter-
individual SGRQ score changes and their relationship 
to clinical outcomes. We also examined the predictive 
validity of the SGRQ for relevant outcomes such as 
morbidity and mortality. 
The development of the database and the results of 
these analyses, which contributed to the endorsement 
of the SGRQ by the FDA, are presented in this current 
Journal issue as a series of  5 papers covering: 
The characteristics of the studies included in the 
database and the baseline demographics of the 
patients and measures which determine baseline 
SGRQ scores.
The demographic determinants of change in 
SGRQ scores.  
The economic determinants of change in SGRQ 
scores. 
The prognostic predictive accuracy of SGRQ.
A definition of response and analysis based on 
responders to interventions. 
“The members of the COPD Biomarkers 
Qualification Consortium dedicate the publication of 
this body of work on the SGRQ to the memory of John 
Walsh--a patient and a truly visionary leader who 
brought us together under a unified call for action. 
John never gave up on the mission of improving 
the lives of patients with COPD, and his passion for 
excellence, sense of urgency and boundless energy 
drove the SGRQ Working Group to this end.”
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